Clinical Trial

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2014-02-19; most recent amendment 2026-03-13.
Status change: Recruiting → Active, Not Recruiting 2022-08-15
Status change: Not Yet Recruiting → Recruiting 2014-11-21
Trial Details
NCT Number NCT02068586
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators: Pfizer
Conditions Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma +4 more
Enrollment 210 participants
Start Date 2014-11-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-16